v3.26.1
SEGMENT AND GEOGRAPHIC INFORMATION (Tables)
 6 Months Ended
Jun. 27, 2026
Segment Reporting [Abstract]  
Schedule of Segment Information
Our reporting segments are as follows:

Reporting Segment
Product Categories
Self Care
Includes over-the-counter health and wellness products intended for consumer self-treatment of common conditions, such as pain & sleep, upper respiratory, digestive health and healthy lifestyle products including vitamins, minerals, and supplements and oral electrolyte beverages
Specialty Care
Includes branded and specialty consumer health products that address more targeted or complex self-care needs, including women's health and skin health offerings, such as skin healing and insect repellant
 Infant Formula
Comprised of the infant formula product category, which includes nutrition products designed to meet the dietary needs of infants
The tables below show select financial measures by reporting segment(1) (in millions):
Three Months EndedSix Months Ended
Net Sales
June 27, 2026June 28, 2025June 27, 2026June 28, 2025
Self Care
$576.6 $598.6 $1,119.9 $1,212.8 
Specialty Care
226.6 233.1 433.6 432.2 
Infant Formula
100.9 82.0 190.6 169.8 
Reporting segment net sales
904.1 913.6 1,744.2 1,814.8 
All Other
118.6 142.7 247.8 285.4 
Total Consolidated net sales
$1,022.8 $1,056.3 $1,992.0 $2,100.2 
Three Months Ended June 27, 2026

Self Care
Specialty Care
Infant Formula
Reporting Segments Total
Reporting segment net sales(2)
576.6 $226.6 $100.9 $904.1 
Adjusted cost of sales402.3 106.1 80.2 
Adjusted other expense items(3)
95.6 72.7 16.8 
Segment operating income$78.7 $47.8 $4.0 $130.5 
Reconciliation to Income from continuing operations before income taxes:
All Other adjusted operating income
25.8 
Unallocated expense
(31.8)
Amortization expense related primarily to acquired intangible assets(54.5)
Impairment charges(4)
(1.0)
Restructuring charges and other termination benefits
(14.4)
Unusual litigation (12.4)
Other(5)
(18.8)
Operating income$23.5 

Six Months Ended June 27, 2026

Self Care
Specialty Care
Infant Formula
Reporting Segments Total
Reporting segment net sales(2)
$1,119.9 $433.6 $190.6 $1,744.2 
Adjusted cost of sales763.5 198.9 159.2 
Adjusted other expense items(3)
209.2 131.6 34.8 
Segment operating income (loss)
$147.3 $103.2 $(3.5)$247.0 
Reconciliation to Income from continuing operations before income taxes:
All Other adjusted operating income
57.6 
Unallocated expense
(67.2)
Amortization expense related primarily to acquired intangible assets(109.0)
Impairment charges(4)
(331.8)
Restructuring charges and other termination benefits
(89.5)
Unusual litigation (28.9)
Other(5)
(27.0)
Operating loss$(348.9)

Three Months Ended June 28, 2025

Self Care
Specialty Care
Infant Formula
Reporting Segments Total
Reporting segment net sales(2)
598.6 $233.1 $82.0 $913.6 
Adjusted cost of sales397.1 98.1 71.2 
Adjusted other expense items(3)
107.6 68.7 23.0 
Segment operating income (loss)$93.9 $66.3 $(12.2)$148.0 
Reconciliation to Income from continuing operations before income taxes:
All Other adjusted operating income
25.7 
Unallocated expense
(38.5)
Amortization expense related primarily to acquired intangible assets(56.8)
Impairment charges(4)
(1.5)
Restructuring charges and other termination benefits
(8.7)
Unusual litigation
(15.4)
Other(5)
(7.4)
Operating income$45.4 
Six Months Ended June 28, 2025

Self Care
Specialty Care
Infant Formula
Reporting Segments Total
Reporting segment net sales(2)
$1,212.8 $432.2 $169.8 $1,814.8 
Adjusted cost of sales785.4 180.2 126.4 
Adjusted other expense items(3)
220.7 143.6 45.0 
Segment operating income (loss)$206.7 $108.4 $(1.6)$313.5 
Reconciliation to Income from continuing operations before income taxes:
All Other adjusted operating income
46.6 
Unallocated expense
(78.3)
Amortization expense related primarily to acquired intangible assets(111.8)
Impairment charges(4)
(4.6)
Infant formula remediation(0.9)
Restructuring charges and other termination benefits
(38.1)
Unusual litigation
(24.3)
Other(5)
(9.8)
Operating income$92.3 

(1) Amounts may not add or recalculate due to rounding.
(2) See table above for reconciliation to Consolidated net sales.
(3) Adjusted other expense items include distribution, research and development, and selling and administrative expenses.
(4) During the three months ended June 27, 2026, we determined the carrying value of an in-process R&D asset was impaired by $1.0 million. During the six months ended June 27, 2026, we also determined the carrying value of our reporting units exceeded their estimated fair value and recorded a goodwill impairment charge of $330.8 million. During the three months ended June 28, 2025, we determined the carrying value of our Prevacid® branded product was impaired by $1.5 million. During the six months ended June 28, 2025, we also determined the carrying value of the Richard Bittner Business net assets held for sale exceeded their fair value less costs to sell, resulting in a total impairment charge of $3.1 million, inclusive of a goodwill impairment charge of $1.2 million.
(5) Other pre-tax adjustments impacting operating income for the three months ended June 27, 2026 includes $3.4 million of professional consulting fees for potential divestiture activity and other legal matters and $15.4 million of accelerated depreciation as a result of a partial plant shut-down to rationalize capacity as part of Nutrition Network Optimization. Other pre-tax adjustments impacting operating income for the six months ended June 27, 2026 includes $11.2 million of professional consulting fees for potential and actual divestiture activity, partially offset by $3.1 million of favorable hedging activity related to the Dermacosmetics Business divestiture, and $18.9 million of accelerated depreciation as part of Nutrition Network Optimization Program. Other pre-tax adjustments for the three months ended June 28, 2025 are related to $4.5 million of accelerated depreciation as a result of Nutrition Network Optimization and $2.8 million of professional consulting fees for divestiture activity. Other pre-tax adjustments for the six months ended June 28, 2025 include expenses of $5.3 million related to professional consulting fees for divestiture activity and $4.5 million related to accelerated depreciation as a result of Nutrition Network Optimization.
The tables below show select financial measures by reporting segment(1) (in millions):
Inventory
June 27, 2026December 31, 2025
Self Care
$668.8 $695.9 
Specialty Care
133.4 146.1 
Infant Formula
170.4 188.4 
All Other
91.7 118.6 
Total inventory
$1,064.5 $1,149.0 

Three Months EndedSix Months Ended
Depreciation
June 27, 2026June 28, 2025June 27, 2026June 28, 2025
Self Care $13.5 $15.4 $27.0 $30.7 
Specialty Care 4.3 3.9 7.4 7.8 
Infant Formula 19.5 8.4 27.2 12.4 
All Other 4.2 1.6 8.4 3.9 
Total depreciation
$41.4 $29.3 $70.1 $54.8 
(1) Amounts may not add or recalculate due to rounding.